
Dennis Miller, R.Ph. is a retired chain store pharmacist. His book, The Shocking Truth About Pharmacy: A Pharmacist Reveals All the Disturbing Secrets, can be downloaded in its entirety at Amazon for 99 cents.
Widespread use of a drug is not proof of its safety.
Prescription-drug commercials present a bizarre spectacle: a promise of a better life accompanied by a list of ways the treatment might damage it. Viewers recognize the contradiction. “That drug could nearly kill you,” they say. Or, “Why would anyone take it?” Yet the warnings seem unable to puncture the confidence surrounding pharmaceuticals. Patients routinely overestimate the potential benefits of a medication and underestimate potential harms (JAMA Internal Medicine, Feb. 2015). We should examine the reasons for this pervasive disconnect. After all, there are warnings about risks on many different platforms.
In my view, the explanation begins with an inflated cultural image of modern medicine: an inexhaustible storehouse of miracle cures, credited with much of the increase in life expectancy over the past century. Once that story is accepted, serious drug risks become easier to rationalize as the unavoidable price of longer lives.
That story deserves far more scrutiny. Critics of medicine’s outsized reputation point instead to better nutrition, sanitation, drinking water, and housing as fundamental drivers of longer lives. They also challenge a medical system that treats preventable diseases of modern civilization with prescriptions rather than confronting their causes. The question is not whether medicine has value. It is whether its prestige has become a substitute for examining what it actually delivers—and at what cost.
My central argument is that this prestige has desensitized us to harm. Warnings remain visible, but the cultural reverence surrounding medicine drains them of urgency. Seven mutually reinforcing habits help explain why.
1. Modern medicine’s prestige shields it from scrutiny
Why can warnings be plainly visible yet leave public confidence largely undisturbed? In my view, modern medicine occupies such an elevated cultural position that criticism of its products can seem less credible than faith in the institution itself.
The reasoning is circular: medicine deserves esteem because it is trustworthy, and its products must be trustworthy because medicine enjoys esteem. Institutional reputation takes the place of a hard examination of benefits, risks, and uncertainty.
Under this protective halo, adverse effects become inconvenient exceptions to a reassuring story. A warning is not treated as a reason to investigate; it is treated as something the respected system must already have considered and contained. Medicine’s reputation does the reassuring before the evidence receives a serious hearing.
A profession should earn confidence through scrutiny—not gain immunity from scrutiny because confidence already exists.
2. Public expectations of the FDA exceed what approval can establish
The FDA is criticized as an agency compromised by pharmaceutical influence, yet it can still serve in the public imagination as an effective guarantee of safety. The assumption seems to be that a drug would never reach the market unless serious uncertainty had already been eliminated.
That assumption is precisely the problem. Approval is treated as the end of the argument rather than the beginning of continued vigilance. In my view, unquestioning faith in the FDA makes criticism seem redundant: surely the watchdog has already done the questioning for us.
Approval should never be mistaken for harmlessness. A regulatory decision cannot substitute for examining the risks relevant to a particular patient. Nor should an agency’s reputation excuse it from scrutiny.
3. Popularity is mistaken for proof of safety
Another comforting assumption follows: surely a drug would not be prescribed so widely if it were not proven safe and effective. But popularity cannot, by itself, establish the quality of the evidence behind a treatment.
“Everyone takes it” is not an answer to “What harm might it do to me?” Familiarity does not resolve uncertainty. Prescription volume does not settle whether a benefit is substantial, whether a risk is acceptable, or whether an alternative deserves consideration.
Widespread use of a drug is not proof of its safety. Repeating that principle is necessary precisely because the opposite assumption is so convenient.
4. Prescription-drug advertising turns warnings into background noise
Direct-to-consumer prescription-drug advertising, permitted only in the United States and New Zealand, packages risk inside a sales pitch. Happy families, sunny afternoons, grandchildren, and the family dog supply the emotional message. The announcer supplies the frightening list of possible harms.
In my view, this is an absurdly inappropriate and manipulative way to present consequential medical choices. The cheerful imagery invites identification with the promised outcome while the warnings pass by as an obligatory interruption.
The uncomfortable question is whether these repeated disclosures sharpen attention—or numb it. A warning can become a familiar ritual: something audiences expect to hear before returning to the advertisement’s promise. The danger is not hidden. It is made routine.
5. Disclosure is mistaken for understanding—and even for reassurance
Reciting a risk is not the same as communicating it. A disclosure does not establish that viewers understand its significance, remember it, or weigh it when deciding what to do. Nor does it overcome the enormous variation in people’s ability to interpret medical warnings.
More perversely, the warning itself may reinforce trust. The audience hears that risks have been disclosed and concludes that responsible authorities must have everything under control. The system receives credit for announcing dangers without necessarily provoking a serious examination of them.
Disclosure thus becomes another rationalization for confidence rather than an invitation to question. There is also a distinction worth insisting on: a manufacturer’s interest in protecting itself against failure-to-warn claims is not the same as a patient’s need to understand the consequences of treatment.
A warning that satisfies a disclosure requirement but fails to inform a decision has not done enough for the patient.
6. Congressional oversight deserves scrutiny, not deference
Big Pharma’s power should make complacency about oversight impossible. Allegations of regulatory capture and lobbying pressure cannot be waved away merely because the FDA bears the title of public watchdog.
My criticism is that public confidence too often outruns scrutiny of the political and commercial forces surrounding approval decisions. When industry can press Congress to demand easier approvals, the independence and resolve of the regulator deserve hard questions—not ceremonial assurances.
If commercial influence shapes regulatory action, the comforting image of a watchdog standing outside competing interests collapses. Congressional oversight is woefully inadequate if it cannot confront that possibility and demand accountability. Asking whose interests prevail is neither cynical nor anti-scientific. It is essential.
7. Professional authority is mistaken for impartial judgment
Physicians and pharmacists are often treated as unbiased guides. Yet professional authority should not make their judgments immune from examination. Familiar prescribing practices can become self-validating: if a treatment belongs to ordinary medical care, its risks begin to feel ordinary too—and therefore less worthy of attention.
The questions patients should ask do not disappear because a recommendation comes from a credentialed professional. What supports the recommendation? How meaningful is the expected benefit? Which risks are being accepted, and why? What alternatives have been considered?
Professional confidence is not a substitute for those answers. Neither is routine use. Widespread use of a drug is not proof of its safety.
Conclusion: Replace reverence with questions
Blind admiration for modern medicine must not displace criticism. We should insist on direct answers: What benefit is expected? How substantial is it? Which harms matter for this patient? What uncertainty remains? What alternatives deserve discussion?
Physicians, pharmacists, and patients should be able to ask these questions without being dismissed as obstructionists, heretics, or therapeutic nihilists. The standard should be neither automatic acceptance nor automatic rejection, but a rigorous examination of benefits, risks, and uncertainty.
Modern medicine should not be allowed to use its prestige to defend a pill-first paradigm. Nor should the assumption that medicine is chiefly responsible for longer lives become a blanket justification for accepting drug-related harm.
FDA approval is not a promise of harmlessness, and a favorable benefit–risk judgment should not end the discussion. How large is the benefit? How serious are the risks? For whom does the trade-off make sense? Those are the questions that the reassuring word “approved” must never silence.
If warnings are to mean anything, they must pierce the halo surrounding modern medicine and its reliance on chemical solutions to the diseases of modern society. A system that expects respect must welcome scrutiny. Otherwise, warnings become background noise—and prestige becomes a license to stop asking questions.
Dennis Miller, R.Ph. is a retired chain store pharmacist. His book, The Shocking Truth About Pharmacy: A Pharmacist Reveals All the Disturbing Secrets, can be downloaded in its entirety at Amazon for 99 cents.
Citations
- Hoffmann TC & Del Mar C, "Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review." JAMA Internal Medicine, Feb. 2015. DOI: 10.1001/jamainternmed.2014.6016